A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

ClinicalTrials.gov processed this data on October 15, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

RECRUITING (See Contacts and Locations)
Verified September 2024 by National Cancer Institute (NCI)

Sponsor

National Cancer Institute (NCI)

Information Provided by (Responsible Party)

National Cancer Institute (NCI)

Clinicaltrials.gov Identifier

NCT06422806
Other Study ID Numbers: NCI-2023-06412
First Submitted: May 18, 2024
First Posted: May 21, 2024
Last Update Posted: October 16, 2024
Last Verified: September 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

PRIMARY OBJECTIVE:

I. To assess whether the combination of doxorubicin and pembrolizumab will improve progression free survival (PFS) in UPS and related poorly differentiated sarcomas relative to doxorubicin alone.

KEY SECONDARY OBJECTIVE:

I. To assess whether the combination of doxorubicin and pembrolizumab versus (vs) the re-introduction of pembrolizumab in the doxorubicin alone arm at disease progression (i.e., upfront pembrolizumab vs second line pembrolizumab) improves overall survival (OS).

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability in each treatment arm. II. To quantify overall response rate (ORR) and durability of response (DOR) in each treatment.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive doxorubicin intravenously (IV) over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. At time of disease progression, patients may begin receiving pembrolizumab alone IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of additional progression or unacceptable toxicity.

Patients in both arms also undergo echocardiogram (ECHO) or multigated acquisition (MUGA) scan during screening, as well as standard imaging scans and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months in years 2-10.
Condition or Disease Intervention/Treatment
  • Metastatic Undifferentiated Pleomorphic Sarcoma
  • Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
  • Unresectable Undifferentiated Pleomorphic Sarcoma
  • Procedure: Biospecimen Collection
  • Procedure: Diagnostic Imaging
  • Drug: Doxorubicin
  • Procedure: Echocardiography
  • Procedure: Multigated Acquisition Scan
  • Biological: Pembrolizumab

Study Design

Study TypeInterventional
Anticipated Enrollment180 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleA Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Study Start DateSeptember 11, 2024
Anticipated Primary Completion DateJune 30, 2026
Anticipated Study Completion DateJune 30, 2026

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Arm A (doxorubicin and pembrolizumab
    • Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA scan during screening, as well as standard imaging scans and blood sample collection throughout the study.
  • Procedure: Biospecimen Collection
    • Undergo blood sample collection
  • Procedure: Diagnostic Imaging
    • Drug: Doxorubicin
      • Procedure: Echocardiography
        • Procedure: Multigated Acquisition Scan
          • Biological: Pembrolizumab
            • Arm B (doxorubicin)
              • Patients receive doxorubicin IV over 3-10 minutes or up to 3 hours on day 1 of each cycle. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. At time of disease progression, patients may begin receiving pembrolizumab alone IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of additional progression or unacceptable toxicity. Patients also undergo ECHO or MUGA scan during screening, as well as standard imaging scans and blood sample collection throughout the study.
            • Procedure: Biospecimen Collection
              • Undergo blood sample collection
            • Procedure: Diagnostic Imaging
              • Drug: Doxorubicin
                • Procedure: Echocardiography
                  • Procedure: Multigated Acquisition Scan

                    Outcome Measures

                    Primary Outcome Measures

                    1. Progression free survival (PFS) [From randomization to documented progression (per Response Evaluation Criteria in Solid Tumors version 1.1) or death from any cause without prior progression, up to 5 years]
                      Will be compared between the treatment arms (doxorubicin + pembrolizumab versus [vs] doxorubicin alone). The comparison of PFS between treatment arms will be done using a stratified (on Eastern Cooperative Oncology group performance status [0 vs 1]) log-rank test with a 5% type I error (1-sided).

                    Secondary Outcome Measures

                    1. Overall survival [From randomization to death, up to 5 years]
                      Will be compared between doxorubicin + pembrolizumab vs doxorubicin alone to test the strategy of upfront pembrolizumab vs second line pembrolizumab.

                    Eligibility Criteria

                    Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
                    Sexes Eligible for Study All
                    Accepts Healthy Volunteers No
                    Inclusion Criteria
                    • Patient must be >= 18 years of age
                    • Patient must have a confirmed histopathologic diagnosis of undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to:
                    • Pleomorphic sarcoma with inflammation or with limited areas of differentiation
                    • Pleomorphic sarcoma with giant cells
                    • Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes)
                    • Myxofibrosarcoma, poorly differentiated sarcoma not otherwise specified (NOS)
                    • Undifferentiated spindle cell sarcoma
                    • Pleomorphic dermal sarcoma
                    • Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation
                    • Patient must have metastatic or unresectable sarcoma
                    • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
                    • Has achieved menarche at some point
                    • Has not undergone a hysterectomy or bilateral oophorectomy; or
                    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
                    • Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 6 months after the last dose of doxorubicin for patients of child bearing potential and for 3 months after the last dose of doxorubicin for male patients with partners of child bearing potential. Males with pregnant partners should use condoms during doxorubicin treatment and for at least 10 days after the last dose of doxorubicin. Contraception measures must also continue for 4 months after the last dose of pembrolizumab for patients of child bearing potential
                    • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
                    • Patient must have a left ventricular ejection Fraction (LVEF) > 50% by either MUGA scan or echocardiogram obtained within 28 days prior to randomization
                    • Absolute neutrophil count (ANC) ≥ 1,500 cells/m^3 (must be obtained ≤ 7 days prior to protocol randomization)
                    • Platelets ≥ 75,000 cells/m^3 (must be obtained ≤ 7 days prior to protocol randomization)
                    • Total bilirubin < 1.2 mg/dL (must be obtained ≤ 7 days prior to protocol randomization)
                    • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 × institutional ULN (must be obtained ≤ 7 days prior to protocol randomization)
                    • Creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (must be obtained ≤ 7 days prior to protocol randomization)
                    • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
                    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
                    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
                    • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
                    • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
                    • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
                    • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
                    • Patient must not have a history of or active interstitial lung disease
                    • Patient must have measurable disease. Baseline imaging must include a chest CT. Imaging should in inclusive of all measurable and non-measurable disease and must be obtained within 28 days prior to randomization. Imaging must be available for uploading to TRIAD
                    • NOTE: CT with (w/) contrast preferred, chest CT without contrast is acceptable, CT portion of positron emission tomography (PET) may be acceptable. Magnetic Resonance Imaging (MRI) is acceptable for measuring other sites of disease
                    • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
                    • Patient must not have had prior treatment with an anthracycline
                    • Patient must not have a diagnosis of clinically significant immunodeficiency or an autoimmune disorder requiring the patient to use systemic steroid chronically, or systemic steroids within 7 days prior to randomization
                    • Patient must not have a known history of active TB (Bacillus Tuberculosis)
                    • Patient must not have a known hypersensitivity to doxorubicin or pembrolizumab or any of their excipients
                    • Patients who have received prior chemotherapy, targeted small molecule therapy or radiation therapy must have recovered from the prior therapy at the time of randomization
                    • Patient must have recovered adequately from any prior major surgery prior to randomization
                    • Patient must not have had prior pericardial or mediastinal radiation
                    • Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent
                    • Patient must not have an autoimmune or other disease that requires the use of daily corticosteroids of > 10 mg of prednisone (or equivalent). Patients who are on an active steroid taper at the time of randomization must finish prior to beginning study treatment. Patients who require inhaled or topical
                    Exclusion Criteria
                    • Patient must be >= 18 years of age
                    • Patient must have a confirmed histopathologic diagnosis of undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Because UPS can sometimes exist in a spectrum among related diagnoses, the following additional diagnostic will be allowed, but not limited to:
                    • Pleomorphic sarcoma with inflammation or with limited areas of differentiation
                    • Pleomorphic sarcoma with giant cells
                    • Malignant fibrous histiocytoma (including storiform-pleomorphic and inflammatory subtypes)
                    • Myxofibrosarcoma, poorly differentiated sarcoma not otherwise specified (NOS)
                    • Undifferentiated spindle cell sarcoma
                    • Pleomorphic dermal sarcoma
                    • Poorly differentiated spindle cell sarcoma NOS Any of these subtypes may have areas of focal myogenic differentiation
                    • Patient must have metastatic or unresectable sarcoma
                    • Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
                    • Has achieved menarche at some point
                    • Has not undergone a hysterectomy or bilateral oophorectomy; or
                    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
                    • Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Contraception measures must continue for 6 months after the last dose of doxorubicin for patients of child bearing potential and for 3 months after the last dose of doxorubicin for male patients with partners of child bearing potential. Males with pregnant partners should use condoms during doxorubicin treatment and for at least 10 days after the last dose of doxorubicin. Contraception measures must also continue for 4 months after the last dose of pembrolizumab for patients of child bearing potential
                    • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
                    • Patient must have a left ventricular ejection Fraction (LVEF) > 50% by either MUGA scan or echocardiogram obtained within 28 days prior to randomization
                    • Absolute neutrophil count (ANC) ≥ 1,500 cells/m^3 (must be obtained ≤ 7 days prior to protocol randomization)
                    • Platelets ≥ 75,000 cells/m^3 (must be obtained ≤ 7 days prior to protocol randomization)
                    • Total bilirubin < 1.2 mg/dL (must be obtained ≤ 7 days prior to protocol randomization)
                    • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 × institutional ULN (must be obtained ≤ 7 days prior to protocol randomization)
                    • Creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (must be obtained ≤ 7 days prior to protocol randomization)
                    • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
                    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
                    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
                    • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
                    • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
                    • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
                    • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
                    • Patient must not have a history of or active interstitial lung disease
                    • Patient must have measurable disease. Baseline imaging must include a chest CT. Imaging should in inclusive of all measurable and non-measurable disease and must be obtained within 28 days prior to randomization. Imaging must be available for uploading to TRIAD
                    • NOTE: CT with (w/) contrast preferred, chest CT without contrast is acceptable, CT portion of positron emission tomography (PET) may be acceptable. Magnetic Resonance Imaging (MRI) is acceptable for measuring other sites of disease
                    • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
                    • Patient must not have had prior treatment with an anthracycline
                    • Patient must not have a diagnosis of clinically significant immunodeficiency or an autoimmune disorder requiring the patient to use systemic steroid chronically, or systemic steroids within 7 days prior to randomization
                    • Patient must not have a known history of active TB (Bacillus Tuberculosis)
                    • Patient must not have a known hypersensitivity to doxorubicin or pembrolizumab or any of their excipients
                    • Patients who have received prior chemotherapy, targeted small molecule therapy or radiation therapy must have recovered from the prior therapy at the time of randomization
                    • Patient must have recovered adequately from any prior major surgery prior to randomization
                    • Patient must not have had prior pericardial or mediastinal radiation
                    • Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA4 agent
                    • Patient must not have an autoimmune or other disease that requires the use of daily corticosteroids of > 10 mg of prednisone (or equivalent). Patients who are on an active steroid taper at the time of randomization must finish prior to beginning study treatment. Patients who require inhaled or topical steroids are eligible

                    Contacts and Locations

                    Sponsors and Collaborators National Cancer Institute (NCI)
                    Locations
                    • Keck Medicine of USC Koreatown | Los Angeles, California, United States, 90020
                    • Los Angeles General Medical Center | Los Angeles, California, United States, 90033
                    • USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States, 90033
                    • USC Norris Oncology/Hematology-Newport Beach | Newport Beach, California, United States, 92663
                    • Beebe South Coastal Health Campus | Millville, Delaware, United States, 19967
                    • Helen F Graham Cancer Center | Newark, Delaware, United States, 19713
                    • Medical Oncology Hematology Consultants PA | Newark, Delaware, United States, 19713
                    • Beebe Health Campus | Rehoboth Beach, Delaware, United States, 19971
                    • Kootenai Health - Coeur d'Alene | Coeur d'Alene, Idaho, United States, 83814
                    • Kootenai Clinic Cancer Services - Post Falls | Post Falls, Idaho, United States, 83854
                    • Kootenai Clinic Cancer Services - Sandpoint | Sandpoint, Idaho, United States, 83864
                    • Illinois CancerCare-Bloomington | Bloomington, Illinois, United States, 61704
                    • Illinois CancerCare-Canton | Canton, Illinois, United States, 61520
                    • Illinois CancerCare-Carthage | Carthage, Illinois, United States, 62321
                    • Centralia Oncology Clinic | Centralia, Illinois, United States, 62801
                    • Northwestern University | Chicago, Illinois, United States, 60611
                    • Carle at The Riverfront | Danville, Illinois, United States, 61832
                    • Cancer Care Specialists of Illinois - Decatur | Decatur, Illinois, United States, 62526
                    • Decatur Memorial Hospital | Decatur, Illinois, United States, 62526
                    • Northwestern Medicine Cancer Center Kishwaukee | DeKalb, Illinois, United States, 60115
                    • Illinois CancerCare-Dixon | Dixon, Illinois, United States, 61021
                    • Carle Physician Group-Effingham | Effingham, Illinois, United States, 62401
                    • Crossroads Cancer Center | Effingham, Illinois, United States, 62401
                    • Elmhurst Memorial Hospital | Elmhurst, Illinois, United States, 60126
                    • Illinois CancerCare-Eureka | Eureka, Illinois, United States, 61530
                    • Illinois CancerCare-Galesburg | Galesburg, Illinois, United States, 61401
                    • Northwestern Medicine Cancer Center Delnor | Geneva, Illinois, United States, 60134
                    • Northwestern Medicine Glenview Outpatient Center | Glenview, Illinois, United States, 60026
                    • Northwestern Medicine Grayslake Outpatient Center | Grayslake, Illinois, United States, 60030
                    • Illinois CancerCare-Kewanee Clinic | Kewanee, Illinois, United States, 61443
                    • Northwestern Medicine Lake Forest Hospital | Lake Forest, Illinois, United States, 60045
                    • Illinois CancerCare-Macomb | Macomb, Illinois, United States, 61455
                    • Carle Physician Group-Mattoon/Charleston | Mattoon, Illinois, United States, 61938
                    • Edward Hospital/Cancer Center | Naperville, Illinois, United States, 60540
                    • Northwestern Medicine Orland Park | Orland Park, Illinois, United States, 60462
                    • Illinois CancerCare-Ottawa Clinic | Ottawa, Illinois, United States, 61350
                    • Illinois CancerCare-Pekin | Pekin, Illinois, United States, 61554
                    • Illinois CancerCare-Peoria | Peoria, Illinois, United States, 61615
                    • Illinois CancerCare-Peru | Peru, Illinois, United States, 61354
                    • Edward Hospital/Cancer Center?Plainfield | Plainfield, Illinois, United States, 60585
                    • Illinois CancerCare-Princeton | Princeton, Illinois, United States, 61356
                    • Southern Illinois University School of Medicine | Springfield, Illinois, United States, 62702
                    • Springfield Clinic | Springfield, Illinois, United States, 62702
                    • Memorial Medical Center | Springfield, Illinois, United States, 62781
                    • Carle Cancer Center | Urbana, Illinois, United States, 61801
                    • Northwestern Medicine Cancer Center Warrenville | Warrenville, Illinois, United States, 60555
                    • Illinois CancerCare - Washington | Washington, Illinois, United States, 61571
                    • Mission Cancer and Blood - Ankeny | Ankeny, Iowa, United States, 50023
                    • Saint Anthony Regional Hospital | Carroll, Iowa, United States, 51401
                    • Mission Cancer and Blood - Des Moines | Des Moines, Iowa, United States, 50309
                    • Broadlawns Medical Center | Des Moines, Iowa, United States, 50314
                    • Trinity Regional Medical Center | Fort Dodge, Iowa, United States, 50501
                    • Dana-Farber Cancer Institute | Boston, Massachusetts, United States, 02215
                    • Essentia Health - Deer River Clinic | Deer River, Minnesota, United States, 56636
                    • Essentia Health Cancer Center | Duluth, Minnesota, United States, 55805
                    • Essentia Health Hibbing Clinic | Hibbing, Minnesota, United States, 55746
                    • Essentia Health Sandstone | Sandstone, Minnesota, United States, 55072
                    • Essentia Health Virginia Clinic | Virginia, Minnesota, United States, 55792
                    • Washington University School of Medicine | Saint Louis, Missouri, United States, 63110
                    • Siteman Cancer Center-South County | Saint Louis, Missouri, United States, 63129
                    • Billings Clinic Cancer Center | Billings, Montana, United States, 59101
                    • Bozeman Health Deaconess Hospital | Bozeman, Montana, United States, 59715
                    • Benefis Sletten Cancer Institute | Great Falls, Montana, United States, 59405
                    • Community Medical Center | Missoula, Montana, United States, 59804
                    • Nebraska Medicine-Bellevue | Bellevue, Nebraska, United States, 68123
                    • Nebraska Medicine-Village Pointe | Omaha, Nebraska, United States, 68118
                    • University of Nebraska Medical Center | Omaha, Nebraska, United States, 68198
                    • Roswell Park Cancer Institute | Buffalo, New York, United States, 14263
                    • Duke University Medical Center | Durham, North Carolina, United States, 27710
                    • UH Seidman Cancer Center at UH Avon Health Center | Avon, Ohio, United States, 44011
                    • UHHS-Chagrin Highlands Medical Center | Beachwood, Ohio, United States, 44122
                    • Miami Valley Hospital South | Centerville, Ohio, United States, 45459
                    • Case Western Reserve University | Cleveland, Ohio, United States, 44106
                    • Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States, 43210
                    • Miami Valley Hospital | Dayton, Ohio, United States, 45409
                    • Premier Blood and Cancer Center | Dayton, Ohio, United States, 45409
                    • Miami Valley Hospital North | Dayton, Ohio, United States, 45415
                    • Atrium Medical Center-Middletown Regional Hospital | Franklin, Ohio, United States, 45005-1066
                    • Miami Valley Cancer Care and Infusion | Greenville, Ohio, United States, 45331
                    • Upper Valley Medical Center | Troy, Ohio, United States, 45373
                    • University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States, 73104
                    • Pennsylvania Hospital | Philadelphia, Pennsylvania, United States, 19107
                    • Virginia Commonwealth University/Massey Cancer Center | Richmond, Virginia, United States, 23298
                    • Duluth Clinic Ashland | Ashland, Wisconsin, United States, 54806
                    • ProHealth D N Greenwald Center | Mukwonago, Wisconsin, United States, 53149
                    • ProHealth Oconomowoc Memorial Hospital | Oconomowoc, Wisconsin, United States, 53066
                    • ProHealth Waukesha Memorial Hospital | Waukesha, Wisconsin, United States, 53188
                    • UW Cancer Center at ProHealth Care | Waukesha, Wisconsin, United States, 53188
                    Investigators
                    • Principal Investigator: Seth M Pollack, ECOG-ACRIN Cancer Research Group

                    More Information

                    Additional Relevant MeSH Terms

                    • Sarcoma
                    • Histiocytoma, Malignant Fibrous
                    • Neoplasms, Connective and Soft Tissue
                    • Neoplasms by Histologic Type
                    • Neoplasms
                    • Histiocytoma
                    • Neoplasms, Fibrous Tissue
                    • Neoplasms, Connective Tissue